Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicplas InternationalSGX:569 EV-to-FCF is -26.29 as of Aug. 03, 2026. The stock has 5 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Vicplas International ranks worse than 239807.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vicplas International's Enterprise Value is S$76.8 Mil.
Vicplas International's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 was S$-2.9 Mil. Therefore, Vicplas International's EV-to-FCF for today is -26.29.
The historical rank and industry rank for Vicplas International's EV-to-FCF or its related term are showing as below:
SGX:569'
s EV-to-FCF Range Over the Past 10 Years
Min: -46.54 Med: 4.1 Max: 57.26
Current: -26.29
During the past 13 years, the highest EV-to-FCF of Vicplas International was 57.26. The lowest was -46.54. And the median was 4.10.
SGX:569's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.52
vs SGX:569: -26.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vicplas International (SGX:569) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vicplas International's PE Ratio (TTM) for today is calculated as:
Vicplas International's share price for today is S$0.077.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vicplas International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 was S$-0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vicplas International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicplas International EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vicplas International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vicplas International's EV-to-FCF falls into.
Vicplas International's current Enterprise Value is S$76.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vicplas International's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 was S$-2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicplas International (SGX:569) has a EV-to-FCF of -26.29 as of Aug. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vicplas International and its competitors. According to the industry distribution chart, Vicplas International ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Vicplas International's EV-to-FCF too high?
Vicplas International's current EV-to-FCF is -26.29. Based on the distribution chart, Vicplas International ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Vicplas International's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vicplas International ranks #999999 out of 417 companies for EV-to-FCF. This places Vicplas International in the lower half of its industry. The industry median EV-to-FCF is 23.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vicplas International and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicplas International's current EV-to-FCF is -26.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicplas International stock overvalued right now?
Based on GuruFocus' analysis, Vicplas International (SGX:569) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.11, compared to a current price of S$0.08 — trading 30% below its estimated fair value. The current EV-to-FCF is -26.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vicplas International (SGX:569), the current EV-to-FCF is -26.29 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicplas International Ltd is an investment holding company. The company is organized into two main business activities: the Pipes and Pipe Fitting segment and the Medical Devices segment, which is the key revenue driver. Pipes and Pipe Fittings segment engages in the manufacturing and distribution of plastic building products, including uPVC pipes and pipe fittings and electrical conduits. The Medical device segment is involved in the research, design, development, and manufacture of medical devices. The company generates majority of its revenue from medical devices. The company does its sales through geographical segments that include Singapore, Malaysia, Mexico, China, and the United Kingdom, of which the majority of the revenue comes from Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:569 has been successfully added to your 
